. En-analyse-univariée, LT CD4<200/mm 3 et CV VIH détectable) et la gravité de l'HTAP (stade NYHA, signes d'insuffisance cardiaque droite, IC bas) En analyse multivariée, l'index cardiaque bas est un facteur de mauvais pronostique, comme dans l'HTAP idiopathique [7], ainsi que le nombre de LT CD4 inférieur à 200/mm 3 , ce qui avait déjà été décrit précédemment dans l'HTAP-VIH, Ce nombre de LTCD4 bas est en

. En-effet and . Dans-notre-série, parmi les patients ayant des CD4 initiaux inférieurs à 200/mm 3 , les décès sont moins liés à l'HTAP que chez les patients ayant des CD4 initiaux supérieurs à

M. Humbert, O. Sitbon, A. Chaouat, M. Bertocchi, G. Habib et al., Pulmonary Arterial Hypertension in France, American Journal of Respiratory and Critical Care Medicine, vol.173, issue.9, pp.173-1023, 2006.
DOI : 10.1164/rccm.200510-1668OC

G. Simonneau, N. Galie, L. J. Rubin, D. Langleben, W. Seeger et al., Clinical classification of pulmonary hypertension, Journal of the American College of Cardiology, vol.43, issue.12, pp.43-48, 2004.
DOI : 10.1016/j.jacc.2004.02.037

R. A. Mesa, E. S. Edell, W. F. Dunn, and W. D. Edwards, Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases, Mayo Clin Proc, issue.1, pp.73-110, 1998.

N. J. Mehta, I. A. Khan, R. N. Mehta, and D. A. Sepkowitz, HIV-Related Pulmonary Hypertension, Chest, vol.118, issue.4, pp.1133-1174, 2000.
DOI : 10.1378/chest.118.4.1133

M. Opravil, M. Pechere, R. Speich, H. I. Joller-jemelka, R. Jenni et al., HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study., American Journal of Respiratory and Critical Care Medicine, vol.155, issue.3, pp.155-990, 1997.
DOI : 10.1164/ajrccm.155.3.9117037

O. Sitbon, C. Lascoux-combe, J. F. Delfraissy, P. G. Yeni, F. Raffi et al., Prevalence of HIV-related Pulmonary Arterial Hypertension in the Current Antiretroviral Therapy Era, American Journal of Respiratory and Critical Care Medicine, vol.177, issue.1, pp.108-121, 2008.
DOI : 10.1164/rccm.200704-541OC

V. V. Mclaughlin, K. W. Presberg, R. L. Doyle, S. H. Abman, D. C. Mccrory et al., Prognosis of Pulmonary Arterial Hypertension*, Chest, vol.126, issue.1, pp.78-92, 2004.
DOI : 10.1378/chest.126.1_suppl.78S

A. Limsukon, A. I. Saeed, V. Ramasamy, J. Nalamati, and S. Dhuper, HIV-related pulmonary hypertension, Mt Sinai J Med, issue.7, pp.73-1037, 2006.

A. M. Pellicelli, F. Palmieri, S. Cicalini, and N. Petrosillo, Pathogenesis of HIV-Related Pulmonary Hypertension, Annals of the New York Academy of Sciences, vol.2, issue.1, pp.82-94, 2001.
DOI : 10.1111/j.1749-6632.2001.tb03904.x

C. D. Cool, D. Kennedy, N. F. Voelkel, and R. M. Tuder, Pathogenesis and evolution of plexiform lesions in pulmonary hypertension associated with scleroderma and human immunodeficiency virus infection, Human Pathology, vol.28, issue.4, pp.434-476, 1997.
DOI : 10.1016/S0046-8177(97)90032-0

M. Humbert, G. Monti, M. Fartoukh, A. Magnan, F. Brenot et al., Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients, Eur Respir J, issue.3, pp.11-554, 1998.

S. A. Mette, H. I. Palevsky, G. G. Pietra, T. M. Williams, E. Bruder et al., Primary Pulmonary Hypertension in Association with Human Immunodeficiency Virus Infection: A Possible Viral Etiology for Some Forms of Hypertensive Pulmonary Arteriopathy, American Review of Respiratory Disease, vol.145, issue.5, pp.145-1196, 1992.
DOI : 10.1164/ajrccm/145.5.1196

N. F. Voelkel, C. D. Cool, and S. Flores, From viral infection to pulmonary arterial hypertension: a role for viral proteins?, AIDS, vol.22, issue.Suppl 3, pp.49-53, 2008.
DOI : 10.1097/01.aids.0000327516.55041.01

M. Humbert, Mediators involved in HIV-related pulmonary arterial hypertension, AIDS, vol.22, issue.Suppl 3, pp.41-48, 2008.
DOI : 10.1097/01.aids.0000327515.55041.da

H. Ehrenreich, P. Rieckmann, F. Sinowatz, K. A. Weih, L. O. Arthur et al., Potent stimulation of monocytic endothelin- 1 production by HIV-1 glycoprotein 120, J Immunol, issue.10, pp.150-4601, 1993.

A. Giaid, M. Yanagisawa, D. Langleben, R. P. Michel, R. Levy et al., Expression of Endothelin-1 in the Lungs of Patients with Pulmonary Hypertension, New England Journal of Medicine, vol.328, issue.24, pp.328-1732, 1993.
DOI : 10.1056/NEJM199306173282402

C. D. Cool, P. R. Rai, M. E. Yeager, D. Hernandez-saavedra, A. E. Serls et al., Expression of Human Herpesvirus 8 in Primary Pulmonary Hypertension, New England Journal of Medicine, vol.349, issue.12, pp.349-1113, 2003.
DOI : 10.1056/NEJMoa035115

H. Nunes, M. Humbert, O. Sitbon, J. H. Morse, Z. Deng et al., Prognostic Factors for Survival in Human Immunodeficiency Virus???associated Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.167, issue.10, pp.167-1433, 2003.
DOI : 10.1164/rccm.200204-330OC

J. P. Zuber, A. Calmy, J. M. Evison, B. Hasse, V. Schiffer et al., Pulmonary Arterial Hypertension Related to HIV Infection: Improved Hemodynamics and Survival Associated with Antiretroviral Therapy, Clinical Infectious Diseases, vol.38, issue.8, pp.38-1178, 2004.
DOI : 10.1086/383037

N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth et al., Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology, Eur Heart J, issue.24, pp.25-2243, 2004.

D. Montani, X. Jais, O. Sitbon, F. Capron, G. Simonneau et al., Pulmonary arterial hypertension, Orphanet Journal of Rare Diseases, vol.8, issue.1, pp.651-66, 2005.
DOI : 10.1378/chest.1456207

URL : https://hal.archives-ouvertes.fr/inserm-00851405

D. B. Badesch, S. H. Abman, G. Simonneau, L. J. Rubin, and V. V. Mclaughlin, Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines, Chest, issue.6, pp.131-1917, 2007.

O. Sitbon, HIV-related pulmonary arterial hypertension: clinical presentation and management, AIDS, vol.22, issue.Suppl 3, pp.55-62, 2008.
DOI : 10.1097/01.aids.0000327517.62665.ec

M. Humbert, O. Sitbon, and G. Simonneau, Treatment of Pulmonary Arterial Hypertension, New England Journal of Medicine, vol.351, issue.14, pp.351-1425, 2004.
DOI : 10.1056/NEJMra040291

URL : https://hal.archives-ouvertes.fr/hal-01455600

S. Miyamoto, N. Nagaya, T. Satoh, S. Kyotani, F. Sakamaki et al., Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing, Am J Respir Crit Care Med, issue.2, pp.161-487, 2000.

P. Yeni, R. Speich, R. Jenni, M. Opravil, M. Pfab et al., Prise en charge médicale des personnes infectées par le VIH Recommandations du groupe d'experts. Rapport Primary pulmonary hypertension in HIV infection, Chest, vol.28, issue.5, pp.100-1268, 1991.

M. Opravil and D. Sereni, Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era, AIDS, vol.22, issue.Suppl 3, pp.35-40, 2008.
DOI : 10.1097/01.aids.0000327514.60879.47

P. Petitpretz, F. Brenot, R. Azarian, F. Parent, B. Rain et al., Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension, Circulation, vol.89, issue.6, pp.2722-2729, 1994.
DOI : 10.1161/01.CIR.89.6.2722

V. Y. Hebert, B. L. Crenshaw, R. L. Romanoff, V. P. Ekshyyan, and T. R. Dugas, Effects of HIV Drug Combinations on Endothelin-1 and Vascular Cell Proliferation, Cardiovascular Toxicology, vol.4, issue.2, pp.117-148, 2004.
DOI : 10.1385/CT:4:2:117

B. Jiang, V. Y. Hebert, J. H. Zavecz, and T. R. Dugas, Antiretrovirals Induce Direct Endothelial Dysfunction In Vivo, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.4, pp.391-396, 2006.
DOI : 10.1097/01.qai.0000228790.40235.0c

A. Pugliese, D. Isnardi, A. Saini, T. Scarabelli, R. Raddino et al., Impact of Highly Active Antiretroviral Therapy in HIV-positive Patients with Cardiac Involvement, Journal of Infection, vol.40, issue.3, pp.282-286, 2000.
DOI : 10.1053/jinf.2000.0672

A. M. Pellicelli, F. Palmieri, C. D-'ambrosio, A. Rianda, E. Boumis et al., Role of Human Immunodeficiency Virus in Primary Pulmonary Hypertension: Case Reports, Angiology, vol.49, issue.12, pp.49-1005, 1998.
DOI : 10.1177/000331979804901206

G. Barbaro, A. Lucchini, A. M. Pellicelli, B. Grisorio, G. Giancaspro et al., Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension, Heart, vol.92, issue.8, pp.92-1164, 2006.
DOI : 10.1136/hrt.2005.076794

W. M. El-sadr, J. D. Lundgren, J. D. Neaton, F. Gordin, D. Abrams et al., CD4+ count-guided interruption of antiretroviral treatment, N Engl J Med, issue.22, pp.355-2283, 2006.

O. Sitbon, V. Gressin, R. Speich, P. S. Macdonald, M. Opravil et al., Bosentan for the Treatment of Human Immunodeficiency Virus???associated Pulmonary Arterial Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.170, issue.11, pp.170-1212, 2004.
DOI : 10.1164/rccm.200404-445OC

B. Degano, A. Yaici, L. Pavec, J. Savale, L. Jais et al., Long-term effects of bosentan in patients with HIVassociated pulmonary arterial hypertension, Eur Respir J, 2008.

R. V. Aguilar and H. W. Farber, Epoprostenol (Prostacyclin) Therapy in HIV-associated Pulmonary Hypertension, American Journal of Respiratory and Critical Care Medicine, vol.162, issue.5, pp.1846-50, 2000.
DOI : 10.1164/ajrccm.162.5.2004042

J. Carlsen, K. Kjeldsen, and J. Gerstoft, Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension, AIDS, vol.16, issue.11, pp.16-1568, 2002.
DOI : 10.1097/00002030-200207260-00021

Y. O. Schumacher, A. Zdebik, M. Huonker, and W. Kreisel, Sildenafil in HIV-related pulmonary hypertension, AIDS, vol.15, issue.13, pp.15-1747, 2001.
DOI : 10.1097/00002030-200109070-00026

L. Highleyman, Protease inhibitors and sildenafil (Viagra) should not be combined, Beta, vol.12, issue.2, p.3, 1999.

N. Galie, L. Rubin, M. Hoeper, P. Jansa, H. Al-hiti et al., Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial, The Lancet, vol.371, issue.9630, pp.371-2093, 2008.
DOI : 10.1016/S0140-6736(08)60919-8

T. C. Quinn, HIV epidemiology and the effects of antiviral therapy on long-term consequences, AIDS, vol.22, issue.Suppl 3, pp.7-12, 2008.
DOI : 10.1097/01.aids.0000327510.68503.e8

M. Egger, M. May, G. Chene, A. N. Phillips, B. Ledergerber et al., Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies, The Lancet, vol.360, issue.9327, pp.360-119, 2002.
DOI : 10.1016/S0140-6736(02)09411-4